199 related articles for article (PubMed ID: 25048167)
1. Nab-paclitaxel: a flattering facelift.
Viúdez A; Ramírez N; Hernández-García I; Carvalho FL; Vera R; Hidalgo M
Crit Rev Oncol Hematol; 2014 Dec; 92(3):166-80. PubMed ID: 25048167
[TBL] [Abstract][Full Text] [Related]
2. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
Lluch A; Alvarez I; Muñoz M; Seguí MÁ; Tusquets I; García-Estévez L
Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy evaluation of albumin-bound paclitaxel.
Cecco S; Aliberti M; Baldo P; Giacomin E; Leone R
Expert Opin Drug Saf; 2014 Apr; 13(4):511-20. PubMed ID: 24559090
[TBL] [Abstract][Full Text] [Related]
4. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.
Vishnu P; Roy V
Womens Health (Lond); 2010 Jul; 6(4):495-506. PubMed ID: 20597612
[TBL] [Abstract][Full Text] [Related]
5. Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers.
Montana M; Ducros C; Verhaeghe P; Terme T; Vanelle P; Rathelot P
J Chemother; 2011 Apr; 23(2):59-66. PubMed ID: 21571619
[TBL] [Abstract][Full Text] [Related]
6. Protein nanoparticles as drug carriers in clinical medicine.
Hawkins MJ; Soon-Shiong P; Desai N
Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
[TBL] [Abstract][Full Text] [Related]
7. [Nab-paclitaxel].
Lopez-Trabada Ataz D; Dumont S; André T
Bull Cancer; 2015 Jun; 102(6):568-76. PubMed ID: 26008630
[TBL] [Abstract][Full Text] [Related]
8. nab-Paclitaxel mechanisms of action and delivery.
Yardley DA
J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
[TBL] [Abstract][Full Text] [Related]
9. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.
Gao M; Zhang D; Jin Q; Jiang C; Wang C; Li J; Peng F; Huang D; Zhang J; Song S
Oncotarget; 2016 Sep; 7(36):58133-58141. PubMed ID: 27531898
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
[TBL] [Abstract][Full Text] [Related]
11. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
[TBL] [Abstract][Full Text] [Related]
12. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
Megerdichian C; Olimpiadi Y; Hurvitz SA
Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant nab-paclitaxel in the treatment of breast cancer.
Ueno NT; Mamounas EP
Breast Cancer Res Treat; 2016 Apr; 156(3):427-440. PubMed ID: 27072366
[TBL] [Abstract][Full Text] [Related]
14. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Dranitsaris G; Coleman R; Gradishar W
Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
[TBL] [Abstract][Full Text] [Related]
15. Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use.
Gaitanis A; Staal S
Methods Mol Biol; 2010; 624():385-92. PubMed ID: 20217610
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma.
Wagner LM; Yin H; Eaves D; Currier M; Cripe TP
Pediatr Blood Cancer; 2014 Nov; 61(11):2096-8. PubMed ID: 24753077
[TBL] [Abstract][Full Text] [Related]
17. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel.
Foote M
Biotechnol Annu Rev; 2007; 13():345-57. PubMed ID: 17875482
[TBL] [Abstract][Full Text] [Related]
18. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
Henderson IC; Bhatia V
Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452
[TBL] [Abstract][Full Text] [Related]
19. The winning formulation: the development of paclitaxel in pancreatic cancer.
Ma WW; Hidalgo M
Clin Cancer Res; 2013 Oct; 19(20):5572-9. PubMed ID: 23918602
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
Petrelli F; Borgonovo K; Barni S
Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]